Sex differences in autoimmune diseases

被引：153

作者：

Voskuhl R. ^{[1
]}

机构：

[1] UCLA Dept. of Neurology, UCLA Multiple Sclerosis Program, Los Angeles, CA 90095

来源：

Biology of Sex Differences | / 2卷 / 1期

基金：

美国国家卫生研究院;

关键词：

Experimental Autoimmune Encephalomyelitis; Multiple Sclerosis Patient; Myelin Basic Protein; Post Partum; Oestrogen Treatment;

D O I：

10.1186/2042-6410-2-1

中图分类号：

学科分类号：

摘要：

Women are more susceptible to a variety of autoimmune diseases including systemic lupus erythematosus (SLE), multiple sclerosis (MS), primary biliary cirrhosis, rheumatoid arthritis and Hashimoto's thyroiditis. This increased susceptibility in females compared to males is also present in animal models of autoimmune diseases such as spontaneous SLE in (NZBxNZW)F1 and NZM.2328 mice, experimental autoimmune encephalomyelitis (EAE) in SJL mice, thyroiditis, Sjogren's syndrome in MRL/Mp-lpr/lpr mice and diabetes in non-obese diabetic mice. Indeed, being female confers a greater risk of developing these diseases than any single genetic or environmental risk factor discovered to date. Understanding how the state of being female so profoundly affects autoimmune disease susceptibility would accomplish two major goals. First, it would lead to an insight into the major pathways of disease pathogenesis and, secondly, it would likely lead to novel treatments which would disrupt such pathways. © 2011 Voskuhl; licensee BioMed Central Ltd.

引用

共 145 条

[1]

Calabresi P.A., Stone L.A., Bash C.N., Frank J.A., McFarland H.F., Interferon beta results in immediate reduction of contrast-enhanced MRI lesions in multiple sclerosis patients followed by weekly MRI, Neurology, 48, 5, pp. 1446-1448, (1997)

[2]

Ge Y., Grossman R.I., Udupa J.K., Fulton J., Constantinescu C.S., Gonzales-Scarano F., Babb J.S., Mannon L.J., Kolson D.L., Cohen J.A., Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: Quantitative MR assessment, Neurology, 54, 4, pp. 813-817, (2000)

[3]

Li D.K.B., Paty D.W., Magnetic resonance imaging results of the PRISMS trial: A randomized, double-blind, placebo-controlled study of interferon-β1a in relapsing- remitting multiple sclerosis, Annals of Neurology, 46, 2, pp. 197-206, (1999)

[4]

Simon J.H., Jacobs L.D., Campion M., Wende K., Simonian N., Cookfair D.L., Rudick R.A., Herndon R.M., Richert J.R., Salazar A.M., Alam J.J., Fischer J.S., Goodkin D.E., Granger C.V., Lajaunie M., Martens-Davidson A.L., Meyer M., Sheeder J., Choi K., Scherzinger A.L., Bartoszak D.M., Bourdette D.N., Braiman J., Brownscheidle C.M., Coats M.E., Cohan S.L., Dougherty D.S., Kinkel R.P., Mass M.K., Munschauer III F.E., Priore R.L., Pullicino P.M., Scherokman B.J., Weinstock-Guttman B., Whitham R.H.,

[5]

Zhao G.J., Koopmans R.A., Li D.K.B., Bedell L., Paty D.W., Effect of interferon β-1b in MS: Assessment of annual accumulation of PD/T2 activity on MRI, Neurology, 54, 1, pp. 200-206, (2000)

[6]

Stevenson V.L., Miller D.H., Leary S.M., Rovaris M., Barkhof F., Brochet B., Dousset V., Dousset V., Filippi M., Hintzen R., Montalban X., Polman C.H., Rovira A., De Sa J., Thompson A.J., One year follow up study of primary and transitional progressive multiple sclerosis, Journal of Neurology Neurosurgery and Psychiatry, 68, 6, pp. 713-718, (2000)

[7]

Rice G.P.A., Filippi M., Comi G., Cladribine and progressive MS: Clinical and MRI outcomes of a multicenter controlled trial, Neurology, 54, 5, pp. 1145-1155, (2000)

[8]

Martin R., McFarland H.F., McFarlin D.E., Immunological aspects of demyelinating diseases, Ann Rev Immunol, 10, 5, pp. 153-187, (1992)

[9]

Waxman S.G., Demyelinating disease - New pathological insights, new therapeutic targets, New England Journal of Medicine, 338, 5, pp. 323-325, (1998)

[10]

Wegmann T.G., Lin H., Guilbert L., Mosmann T.R., Bidirectional cytokine interactions in the maternal-fetal relationship: Is successful pregnancy a T(H)2 phenomenon?, Immunology Today, 14, 7, pp. 353-356, (1993)

← 1 2 3 4 5 6 7 8 9 10 →